Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPH3AL antisense RNA 1 (RPH3AL-AS1) is a long non-coding RNA (lncRNA) gene transcribed from the antisense strand at the RPH3AL locus on chromosome 17 (17p13.3). Like other natural antisense transcripts, it is presumed to modulate the expression of its sense gene (RPH3AL), most likely through RNA-RNA interaction mechanisms that regulate translation or stability of the target mRNA. RPH3AL-AS1 itself is classified as a non-coding RNA and does not encode a protein product. There is no published evidence for direct therapeutic targeting, involvement in disease, or known pharmacological interactors of RPH3AL-AS1 to date. Its primary role is thought to be regulation of gene expression at the transcriptional or post-transcriptional level, but detailed functional characterization is lacking.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RPH3AL antisense RNA 1 (RPH3AL-AS1).